Pembrolizumab, drug EV, and radiation for bladder cancer
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This Phase 2 study tests how well pembrolizumab and an antibody-drug medicine (EV) given with bladder radiation work for non-metastatic bladder cancer that is mostly urothelial. It may help some people control the cancer without it spreading to other organs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and were recently diagnosed with muscle-invasive bladder cancer (MIBC) mostly urothelial type based on a recent TURBT biopsy within 90 days.
- Your bladder cancer has not spread to other organs on scans (N0M0) using CT chest and CTU/MRU of the abdomen/pelvis.
- You must be able to give written consent and do the required clinic visits and tests during the study.
- Your overall health must be good enough for treatment (ECOG performance status 0 to 1) and checked within 7 days of starting.
- Your lab tests and organ function must be adequate, with screening blood/urine tests done within 10 days of starting.
- You must not have certain bladder tumor patterns or medical conditions that would make treatment unsafe (for example, extensive CIS in many spots, prior pelvic radiation, or certain nerve/immune/lung problems).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests adding new treatments to a standard therapy (enfortumab vedotin and pembrolizumab) for people with advanced bladder cancer that hasn't been treated before. It aims to find out if these combinations are safe and work better.
This trial studies pembrolizumab (an immunotherapy) in people with muscle-invasive bladder cancer who had a combined “trimodality” treatment and then achieved a complete response. The goal is to help control the cancer after the initial treatment is finished.
This trial tests a combination of two drugs (enfortumab vedotin and pembrolizumab) plus radiation therapy for people with bladder cancer that has grown into the muscle layer. The goal is to see if this treatment can kill the cancer while avoiding the need for bladder removal surgery.
This trial tests whether adding radiation therapy to immunotherapy after bladder removal surgery can help prevent cancer from coming back. It's for people with advanced bladder cancer who have already started immunotherapy.
This trial tests whether adding the immunotherapy drug pembrolizumab to radiation therapy works as well as or better than the usual chemotherapy given with radiation for a type of bladder cancer that has not invaded the muscle. It is for people whose cancer came back or has high-risk features and who would otherwise need to have their bladder removed.
This study tests whether adding an immunotherapy drug (cemiplimab) with or without another drug (fianlimab) to radiation therapy can help treat bladder cancer that has not spread. The goal is to see if this combination could be an option for people who cannot have cisplatin chemotherapy.
Hear when a new Bladder Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.